Cita APA (7a ed.)
Biswas, S., Srivastava, Y., & Hamadttu, A. (2026 Supplement 19). Real-world comparison of cabozantinib versus regorafenib as second-line therapy for advanced hepatocellular carcinoma after first-line immune checkpoint inhibitors: A propensity score–matched analysis. Journal of Clinical Oncology, 44, 132-198.
Cita Chicago Style (17a ed.)
Biswas, Shankar, Yashasvi Srivastava, y Ayman Hamadttu. "Real-world Comparison of Cabozantinib Versus Regorafenib as Second-line Therapy for Advanced Hepatocellular Carcinoma After First-line Immune Checkpoint Inhibitors: A Propensity Score–matched Analysis." Journal of Clinical Oncology 44 (2026 Supplement 19): 132-198.
Cita MLA (9a ed.)
Biswas, Shankar, et al. "Real-world Comparison of Cabozantinib Versus Regorafenib as Second-line Therapy for Advanced Hepatocellular Carcinoma After First-line Immune Checkpoint Inhibitors: A Propensity Score–matched Analysis." Journal of Clinical Oncology, vol. 44, 2026 Supplement 19, pp. 132-198.
Precaución: Estas citas no son 100% exactas.